Patient Medication Information: uses, side effects, how to take - Mint-Zolmitriptan ODT
WHAT THE MEDICATION IS USED FOR:
MINT-ZOLMITRIPTAN and MINT-ZOLMITRIPTAN ODT belong to a group of anti- migraine drugs called 5-HT1 agonists. MINT-ZOLMITRIPTAN /MINT-ZOLMITRIPTAN ODT is used to relieve your migraine headache and other associated symptoms of a migraine attack.
MINT-ZOLMITRIPTAN /MINT-ZOLMITRIPTAN ODT should not be used continuously to prevent or reduce the number of attacks you experience. Use MINT-ZOLMITRIPTAN /MINT-ZOLMITRIPTAN ODT only to treat an actual migraine headache attack.
WHAT IT DOES:
Migraine headache is believed to be caused by a widening of the blood vessels in the head. MINT-ZOLMITRIPTAN /MINT-ZOLMITRIPTAN ODT narrows the vessels and relieves the pain and other symptoms of migraine headache.
WHEN IT SHOULD NOT BE USED:
MINT-ZOLMITRIPTAN /MINT-ZOLMITRIPTAN ODT should not be used if:
- you are allergic to zolmitriptan or any of the other ingredients in MINT-ZOLMITRIPTAN /MINT-ZOLMITRIPTAN ODT (see “WHAT THE NONMEDICINAL INGREDIENTS ARE”)
- you have a history, or any symptoms or signs of a heart condition
- you have severe or uncontrolled hypertension
you are taking or have recently taken (within 24 hours)
an ergotamine containing or ergot-like drug, or another triptan used to treat migraines
- you have another type of headache that is different from a migraine attack
- you are taking or have recently taken (within 2 weeks) a monoamine oxidase inhibitor (MAOI)
WHAT THE MEDICINAL INGREDIENT IS: Both MINT-ZOLMITRIPTAN and MINT-
ZOLMITRIPTAN ODT tablets contain 2.5 mg of zolmitriptan as the active ingredient.
WHAT THE IMPORTANT NONMEDICINAL INGREDIENTS ARE:
MINT-ZOLMITRIPTAN contains: HPMC
2910/Hypromellose 5 cP , Iron Oxide Red, Lactose Anhydrous, Macrogol/Peg 400, Macrogol/Peg 8000, Magnesium Stearate, Microcrystalline Cellulose, Purified water, Sodium Starch Glycolate, Titanium Dioxide.
MINT-ZOLMITRIPTAN ODT contains: Acesulfame Potassium, Acetone, Amino Methacrylate Copolymer, Colloidal Silicon Dioxide, Crospovidone (Polyplasdone XL – 10), Isopropyl Alcohol, Low-Substituted Hydroxypropyl Cellulose, Magnesium
Aluminometasilicate, Magnesium Stearate, Maltodextrin, Mannitol, Modified Corn Starch, Natural Flavours, Purified Water, Sodium Lauryl Sulphate, Talc.
WHAT DOSAGE FORMS IT COMES IN: MINT-ZOLMITRIPTAN is supplied in conventional tablets of 2.5 mg in blister packs containing 6 tablets. MINT-ZOLMITRIPTAN ODT is supplied in orally dispersible tablets of 2.5 mg in blister packs containing 6 tablets.
WARNINGS AND PRECAUTIONSdddddddd
BEFORE you use MINT-ZOLMITRIPTAN /MINT-ZOLMITRIPTAN ODT talk to your doctor or pharmacist if the answer to any of the following questions is YES, or if you do not know the answer:
Are you pregnant, think you might be pregnant, or trying to become pregnant? Are you using inadequate contraception? Are you breastfeeding?
- Do you or have you ever experienced any pain or tightness in the chest, (which may or may not spread to your neck, jaw, or upper arm), shortness of breath, or irregular heart beats? Do you have angina? Have you ever had heart or blood vessel disease? Do you have a history of cerebral bleeding? Have you had a heart
attack or stroke?
Do you have risk factors for heart disease, such as:
high blood pressure, high cholesterol, smoking, obesity, diabetes, or strong family history of heart disease?
Do you have rare hereditary problems of
galactose intolerance?
- Are you post-menopausal or a male over 40?
- Do you have high blood pressure?
Have you ever had to stop taking this or any other
medication because of an allergy or other problems?
Are you taking any other migraine 5-HT1 agonist
medications such as sumatriptan succinate, naratriptan hydrochloride, rizatriptan benzoate, almotriptan malate or migraine medications containing ergotamine, dihydroergotamine, or methysergide?
Are you taking any medications for depression such as
selective serotonin reuptake inhibitors (SSRI’s), for example, fluoxetine hydrochloride, sertraline hydrochloride, fluvoxamine maleate, paroxetine hydrochloride, etc., or serotonin norepinephrine reuptake inhibitors (SNRIs), for example, venlafaxine hydrochloride, or monoamine oxidase inhibitors (MAOIs), for example, phenelzine sulfate, tranylcypromine sulfate or moclobemide?
Have you ever experienced numbness on one side of
your body when you have a headache?
- Have you ever had epilepsy or seizures?
- Have you ever had liver disease?
- Are you over 65 years of age?
Is this headache different from your usual migraine
attacks?
Are you taking cimetidine (for treatment of indigestion or
stomach ulcers) or a member of the quinolone family of antibiotics (for example ciprofloxacin)?
If you use MINT-ZOLMITRIPTAN /MINT-
ZOLMITRIPTAN ODT too often, it may make your headaches worse. If this happens, your doctor may tell you to stop taking MINT-ZOLMITRIPTAN /MINT-ZOLMITRIPTAN ODT.
MINT-ZOLMITRIPTAN tablets contain lactose which is a type of sugar. If you have been told by your doctor that you cannot tolerate or digest milk or some sugars, talk to your doctor before taking this medicine.
Use of MINT-ZOLMITRIPTAN /MINT-
ZOLMITRIPTAN ODT during pregnancy: Do not use MINT-ZOLMITRIPTAN or MINT-ZOLMITRIPTAN ODT if you are pregnant, think you might be pregnant, are trying to become pregnant or are using inadequate contraception, unless you have discussed this with your doctor.
INTERACTIONS WITH THIS MEDICATIONcddddc
Tell your doctor or pharmacist about any other drugs you take, including:
other 5-HT1 agonist migraine drugs (sumatriptan
succinate, naratriptan hydrochloride, rizatriptan benzoate, almotriptan malate) or migraine drugs that contain ergotamine, dihydroergotamine, methysergide
- drugs for depression such as selective serotonin reuptake inhibitors (SSRI’s), for example, fluoxetine hydrochloride, sertraline hydrochloride, fluvoxamine maleate, paroxetine hydrochloride, etc., or serotonin norepinephrine reuptake inhibitors (SNRIs), for example, venlafaxine hydrochloride, or monoamine oxidase inhibitors (MAOIs), for example, phenelzine sulfate, tranylcypromine sulfate or moclobemide
- drugs used to treat upset stomach or stomach ulcers (cimetidine)
antibiotics from the quinolone family (for
example ciprofloxacin)
Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, even those that can be bought without a prescription.
dddddPROPER USE OF THIS MEDICATIONdddddd
USUAL DOSE:
Adults
The usual dosage is 2.5 mg, or lower if recommended by your doctor. A lower dose can be obtained by manually breaking a conventional tablet in half. The MINT-ZOLMITRIPTAN ODT 2.5 mg orally dispersible tablets cannot be broken in half. The dose should be taken as soon as your migraine appears, but it may be taken at any time during your migraine headache. Swallow your dose with water.
For MINT-ZOLMITRIPTAN ODT orally dispersible tablets, the blister pack should be peeled open as shown on the foil (tablets should not be pushed through the foil). The MINT-ZOLMITRIPTAN ODT tablet should be placed on the tongue, where it will dissolve with the saliva. Water is not needed for the dispersible tablet.
A second dose may be taken if your headache returns, but not sooner than 2 hours following the first tablet. For any attack where you have no response to the first dose, do not take a second dose without first consulting your doctor.
Do not administer more than 10 mg in any 24 hour period.
OVERDOSE:
If you have taken more medication than your doctor has instructed, contact either your doctor, hospital emergency department, or nearest poison control centre immediately.
In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.
SIDE EFFECTS AND WHAT TO DO ABOUT THEMd
Although the vast majority of zolmitriptan conventional tablets and zolmitriptan orally disintegrating tablets users have not experienced any significant problems, you should be aware that the following side effects may occur.
Commonly reported side effects of zolmitriptan conventional tablets and zolmitriptan orally disintegrating tablets are:
- feeling sick
- vomiting
- dizziness
- tiredness
- weakness
MINT-ZOLMITRIPTAN / MINT-ZOLMITRIPTAN ODT may cause drowsiness. Do not drive or operate machinery until you are sure that you are not drowsy.
Other common side effects include:
- muscle aches and pains
- difficulty swallowing
- dry mouth
- headache
- stomach pain
Uncommon side effects include:
increase in the production of urine or in the frequency
of urination
Tell your doctor of these symptoms at your next visit.
Migraineurs may be at risk of certain cerebrovascular events such as cerebral bleeding and stroke. In very rare cases, as with other drugs of this type, such diseases have been reported in association with the use of zolmitriptan.
In very rare cases, as with other drugs of this type (5HT1 agonists), the following side effects have been reported:
- spasm of the blood vessels of the heart
spasm of the blood vessels of the Gastro-Intestinal tract
and spleen with possible infarctions
See the following table for what to do about serious side effects.
| SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM | |||
| Symptom / effect | Talk with your doctor or pharmacist | Stop taking drug and call your doctor or pharmacist | |
| Only if severe | In all cases | ||
| Common (frequency greater than or equal to 1% but in less than 10% of patients) | |||
| Irregular heart beat | √ | ||
| Sensations of pain, pressure or tightness in the chest, neck, | √ | ||
| SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM | |||
| Symptom / effect | Talk with your doctor or pharmacist | Stop taking drug and call your doctor or pharmacist | |
| Only if severe | In all cases | ||
| throat, jaw, arms, or legs | |||
| Sensations of tingling, heat, heaviness or pressure | √ | ||
| Uncommon (frequency greater than or equal to 0.1% but in less than 1% of patients) | |||
| Fast heart rate | √ | ||
Temporary increase in blood pressure | √ | ||
| Rare (frequency greater than or equal to 0.01% but in less than 0.1% of patients) | |||
Shortness of breath, wheeziness, heart throbbing, swelling of the eyelids, face, or lips; or a skin rash, itchy rash, skin lumps or hives, or swelling with fluid in the tissues | √ | ||
| Very rare (frequency in less than 0.01% of patients) | |||
Symptoms of a heart attack (chest pain, sweating, shortness of breath) | √ | ||
Sudden or severe abdominal pain or bloody diarrhea | √ | ||
For any unexpected effects while taking MINT-ZOLMITRIPTAN /MINT-ZOLMITRIPTAN ODT, contact your doctor or pharmacist.
HOW TO STORE ITccccccccccccccccccc
Keep your medicine in a safe place where children cannot reach it. MINT-ZOLMITRIPTAN and MINT-ZOLMITRIPTAN ODT could be harmful to children. Store your medication between 15oC and 30ºC, away from direct heat.
If your doctor decides to stop your treatment, return your medicine to the pharmacist for disposal. Do not take your medication after the expiry date on the package and blister foil. Return the tablets to your pharmacist for disposal.
REPORTING SUSPECTED SIDE EFFECTS
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:
- Report online at www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
Complete a Canada Vigilance Reporting Form and:
- Fax toll-free to 1-866-678-6789, or
Mail to: Canada Vigilance Program
Health Canada
Ottawa, ON K1A 0K9 Postal Locator 0701E
Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at
www.healthcanada.gc.ca/medeffect.
NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.
MORE INFORMATIONdddddddddddd
NOTE: This CONSUMER INFORMATION leaflet provides you with the most current information at the time of printing.
For the most current information, the Consumer Information Leaflet plus the full Product Monograph, prepared for health professionals can be found at: or by contacting the sponsor, Mint Pharmaceuticals Inc. at: Mint Pharmaceuticals Inc., 1093 Meyerside Drive, Unit 1, Mississauga, Ontario L5T 1J6
Date of Preparation: 16 January 2014
